Target Information

Target General Infomation
Target ID
T65755
Former ID
TTDC00297
Target Name
Histone deacetylase
Synonyms
HD; HDAC
Target Type
Successful
Disease Autoimmune diabetes [ICD10: E08-E13]
Cancer [ICD9: 140-229; ICD10: C00-C96]
Cutaneous T-cell lymphoma [ICD9: 202.1, 202.2; ICD10: C84.0, C84.1]
Epilepsy [ICD10: G40]
HIV-1 infection [ICD9: 001-139, 042; ICD10: B20-B24]
Keratosis [ICD10: L57.0]
Lymphoma [ICD9: 202.8, 208.9; ICD10: C81-C86]
Multiple myeloma [ICD9: 203; ICD10: C90]
Myelodysplastic syndrome; Myelofibrosis [ICD9:238.7, 208.9, 289.83, 709.2; ICD10: D46, C94.4, D47.4]
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10: M05-M06]
Rhinovirus infection [ICD10: J20.6?]
Spinal muscular atrophy [ICD9: 335.0-335.1; ICD10: G00-G99]
Function
Responsible for the deacetylation of lysine residues on the n-terminal part of the core histones (H2a, H2b, H3 and H4). Histone deacetylation givesa tag for epigenetic repression and plays an important role in transcriptional regulation.
BioChemical Class
Carbon-nitrogen hydrolase
Target Validation
T65755
EC Number
EC 3.5.1.-
Drugs and Mode of Action
Drug(s) Sodium phenylbutyrate Drug Info Approved Spinal muscular atrophy [1]
Valproic Acid Drug Info Approved Epilepsy [2], [3], [4]
CMS-024-02 Drug Info Phase 3 Cancer [5]
Abexinostat Drug Info Phase 2 Cancer [6], [7]
APH-0812 Drug Info Phase 2 HIV-1 infection [8], [9]
DAC-060 Drug Info Phase 2 Keratosis [10]
JNJ-26481585 Drug Info Phase 2 Cancer [11], [12]
PDX-101 Drug Info Phase 2 Cancer [13]
Pracinostat Drug Info Phase 2 Myelodysplastic syndrome; Myelofibrosis [14], [15]
Rocilinostat Drug Info Phase 2 Multiple myeloma [16]
ACY-1215 Drug Info Phase 1/2 Autoimmune diabetes [17], [18]
CG-200745 Drug Info Phase 1 Cancer [19]
CT-200 Drug Info Phase 1 Cancer [20]
CXD-101 Drug Info Phase 1 Cancer [21]
GSK311739 Drug Info Phase 1 Rhinovirus infection [22]
GSK3117391 Drug Info Phase 1 Rheumatoid arthritis [23]
SHAPE Drug Info Phase 1 Lymphoma [24]
SHP-141 Drug Info Phase 1 Cutaneous T-cell lymphoma [25]
CS-00028 Drug Info Preclinical Cancer [26]
MKC-1313 Drug Info Terminated Cancer [27]
Inhibitor (E)-8-Biphenyl-4-yl-1-oxazol-2-yl-oct-7-en-1-one Drug Info [28]
2,2-bis(3-fluorophenyl)-N-hydroxyacetamide Drug Info [29]
2,2-bis(4-chlorophenyl)-N-hydroxyacetamide Drug Info [29]
2,2-bis(4-fluorophenyl)-N-hydroxyacetamide Drug Info [29]
2-(methylsulfonylthio)ethyl 2-propylpentanoate Drug Info [30]
4-Benzoylamino-N-hydroxy-benzamide Drug Info [31]
4-Butyrylamino-N-hydroxy-benzamide Drug Info [32]
4-Chloro-N-(5-hydroxycarbamoyl-pentyl)-benzamide Drug Info [33]
4-Dimethylamino-N-(6-mercapto-hexyl)-benzamide Drug Info [34]
4-Hydroxy-N-(5-hydroxycarbamoyl-pentyl)-benzamide Drug Info [33]
4-Phenylbutyrohydroxamic acid Drug Info [35]
5-(4-Chloro-phenyl)-pentanoic acid hydroxyamide Drug Info [36]
5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione Drug Info [30]
5-Mercapto-pentanoic acid phenylamide Drug Info [34]
6-(2-Bromo-acetylamino)-hexanoic acid phenylamide Drug Info [34]
6-benzenesulfinylhexanoic acid hydroxamide Drug Info [37]
6-benzenesulfonylhexanoic acid hydroxamide Drug Info [37]
6-Mercapto-hexanoic acid phenylamide Drug Info [34]
6-Phenoxy-hexane-1-thiol Drug Info [34]
6-phenylsulfanylhexanoic acid hydroxamide Drug Info [37]
7-(Biphenyl-3-yloxy)-1-oxazol-2-yl-heptan-1-one Drug Info [28]
7-(Biphenyl-4-yloxy)-1,1,1-trifluoro-heptan-2-one Drug Info [38]
7-(Biphenyl-4-yloxy)-1-oxazol-2-yl-heptan-1-one Drug Info [28]
7-(Naphthalen-2-yloxy)-1-oxazol-2-yl-heptan-1-one Drug Info [28]
7-Mercapto-heptanoic acid benzothiazol-2-ylamide Drug Info [34]
7-Mercapto-heptanoic acid biphenyl-3-ylamide Drug Info [34]
7-Mercapto-heptanoic acid biphenyl-4-ylamide Drug Info [34]
7-Mercapto-heptanoic acid phenylamide Drug Info [34]
7-Mercapto-heptanoic acid pyridin-3-ylamide Drug Info [34]
7-Mercapto-heptanoic acid quinolin-3-ylamide Drug Info [34]
8-(Biphenyl-4-yloxy)-1,1,1-trifluoro-octan-2-one Drug Info [28]
8-Mercapto-octanoic acid phenylamide Drug Info [34]
8-Oxo-8-phenyl-octanoic acid Drug Info [33]
8-Oxo-8-phenyl-octanoic acid hydroxyamide Drug Info [38]
9,9,9-Trifluoro-8-oxo-nonanoic acid phenylamide Drug Info [38]
9-(Biphenyl-4-yloxy)-1,1,1-trifluoro-nonan-2-one Drug Info [38]
APH-0812 Drug Info [8], [9]
Apicidin Drug Info [39], [40], [41]
Azelaic bishydroxamic acid Drug Info [40]
CG-1521 Drug Info [40]
CG-200745 Drug Info [42]
CHAP1 Drug Info [43], [41]
CHAP31 Drug Info [43], [41]
CT-200 Drug Info [44]
CXD-101 Drug Info [45]
Cyclostellettamine derivative Drug Info [46]
DAC-060 Drug Info [47]
LBH539 Drug Info [48]
MKC-1313 Drug Info [49]
N-(2,3-Dimethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(2,4-Dimethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(2,5-Dimethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(2,6-Dimethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(2-amino-5-(thiophen-2-yl)phenyl)nicotinamide Drug Info [51]
N-(2-aminophenyl)-4-methoxybenzamide Drug Info [52]
N-(2-aminophenyl)nicotinamide Drug Info [51]
N-(2-Ethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(2-Mercapto-ethyl)-N'-phenyl-oxalamide Drug Info [53]
N-(2-Mercapto-ethyl)-N'-phenyl-succinamide Drug Info [53]
N-(3,4-Dimethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(3,5-Dimethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(3-Ethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(4-aminobiphenyl-3-yl)nicotinamide Drug Info [51]
N-(4-Ethylphenyl)-N'-hydroxyoctanediamide Drug Info [50]
N-(5-Hydroxycarbamoyl-pentyl)-4-methoxy-benzamide Drug Info [54]
N-(5-Hydroxycarbamoyl-pentyl)-4-nitro-benzamide Drug Info [33]
N-(5-Hydroxycarbamoyl-pentyl)-benzamide Drug Info [54]
N-(6-Hydroxycarbamoyl-hexyl)-benzamide Drug Info [33]
N-(6-Mercapto-hexyl)-benzamide Drug Info [34]
N-hydroxy-2,2-diphenylacetamide Drug Info [29]
N-hydroxy-2,2-diphenylpropanamide Drug Info [29]
N-Hydroxy-4-((R)-2-phenyl-butyrylamino)-benzamide Drug Info [31]
N-Hydroxy-4-((S)-2-phenyl-butyrylamino)-benzamide Drug Info [31]
N-Hydroxy-4-(2-phenyl-butyrylamino)-benzamide Drug Info [31]
N-Hydroxy-4-(3-phenyl-propionylamino)-benzamide Drug Info [31]
N-Hydroxy-4-(4-phenyl-butyrylamino)-benzamide Drug Info [31]
N-Hydroxy-4-(5-phenyl-pentanoylamino)-benzamide Drug Info [31]
N-Hydroxy-4-(pentanoylamino-methyl)-benzamide Drug Info [32]
N-Hydroxy-4-(phenylacetylamino-methyl)-benzamide Drug Info [32]
N-Hydroxy-4-phenylacetylamino-benzamide Drug Info [31]
N-hydroxy-9,10-dihydroanthracene-9-carboxamide Drug Info [29]
N-hydroxy-9H-xanthene-9-carboxamide Drug Info [29]
N-Hydroxy-N'-(2-methylphenyl)octanediamide Drug Info [50]
N-Hydroxy-N'-(3-methylphenyl)octanediamide Drug Info [50]
N-Hydroxy-N'-(4-methoxyphenyl)octanediamide Drug Info [50]
N-Hydroxy-N'-(4-methylphenyl)octanediamide Drug Info [50]
N1-(biphenyl-4-yl)-N8-hydroxyoctanediamide Drug Info [55]
Octanedioic acid bis-hydroxyamide Drug Info [35]
Octanedioic acid hydroxyamide pyridin-2-ylamide Drug Info [33]
Octanedioic acid hydroxyamide pyridin-4-ylamide Drug Info [33]
PSAMMAPLIN A Drug Info [38]
Rocilinostat Drug Info [56]
SHAPE Drug Info [57]
Sodium phenylbutyrate Drug Info [58], [4]
ST-2986 Drug Info [59]
ST-2987 Drug Info [59]
ST-3050 Drug Info [59]
ST-5732 Drug Info [60]
Suberic bishydroxamic acid Drug Info [40]
Thioacetic acid S-(6-phenylcarbamoyl-hexyl) ester Drug Info [34]
Trapoxin Drug Info [43]
Trichostatin A Drug Info [61], [41], [62]
Trifluoromethylketone Drug Info [40]
Valproic Acid Drug Info [63], [40], [62], [64], [65]
Modulator Abexinostat Drug Info [66]
ACY-1215 Drug Info [67]
CMS-024-02 Drug Info [68]
GSK311739 Drug Info [69]
GSK3117391 Drug Info [70]
JNJ-26481585 Drug Info [12]
PDX-101 Drug Info [71]
Pracinostat Drug Info [14]
SHP-141 Drug Info [72]
Antagonist CS-00028 Drug Info [73]
References
REF 1ClinicalTrials.gov (NCT00533559) Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl. U.S. National Institutes of Health.
REF 2Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
REF 3(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7009).
REF 4Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
REF 5ClinicalTrials.gov (NCT01489566) Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients. U.S. National Institutes of Health.
REF 6(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8366).
REF 7Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022814)
REF 8Bryostatin-1: a novel PKC inhibitor in clinical development. Cancer Invest. 2003;21(6):924-36.
REF 9Targeting the protein kinase C family: are we there yet. Nat Rev Cancer. 2007 Jul;7(7):554-62.
REF 10Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031213)
REF 11JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51.
REF 12(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503).
REF 13A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2015 Mar;168(6):811-9.
REF 14(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
REF 15Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026393)
REF 16Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032606)
REF 17ClinicalTrials.gov (NCT02091063) ACY-1215 for Relapsed/Refractory Lymphoid Malignancies. U.S. National Institutes of Health.
REF 18(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7010).
REF 19ClinicalTrials.gov (NCT01226407) Examine Maximum Tolerated Dose and Pharmacokinetic and Pharmacodynamic Profile. U.S. National Institutes of Health.
REF 20Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027375)
REF 21ClinicalTrials.gov (NCT01977638) Phase 1 Trial of CXD101 in Patients With Advanced Cancer. U.S. National Institutes of Health.
REF 22Biopharmaceutical Research Companies Are Developing More Than 430 Medicines for Top Chronic Diseases Affecting Older Americans. Pharmaceutical Research and Manufacturers of America report. 2014.
REF 23Clinical pipeline report, company report or official report of GlaxoSmithKline.
REF 24Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
REF 25ClinicalTrials.gov (NCT01646567) SHP-141C in Plaque Type Psoriasis. U.S. National Institutes of Health.
REF 26Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021167)
REF 27Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024821)
REF 28Bioorg Med Chem Lett. 2003 Nov 17;13(22):3909-13.Heterocyclic ketones as inhibitors of histone deacetylase.
REF 29Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. Epub 2009 Aug 7.Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.
REF 30Bioorg Med Chem Lett. 2008 Mar 15;18(6):1893-7. Epub 2008 Feb 8.New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity.
REF 31J Med Chem. 2005 Aug 25;48(17):5530-5.Structure-based optimization of phenylbutyrate-derived histone deacetylase inhibitors.
REF 32J Med Chem. 2004 Jan 15;47(2):467-74.Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.
REF 33J Med Chem. 2002 Feb 14;45(4):753-7.Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.
REF 34J Med Chem. 2005 Feb 24;48(4):1019-32.Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
REF 35Nat Chem Biol. 2010 Mar;6(3):238-243. Epub 2010 Feb 7.Chemical phylogenetics of histone deacetylases.
REF 36Bioorg Med Chem Lett. 2004 May 17;14(10):2477-81.Stereodefined and polyunsaturated inhibitors of histone deacetylase based on (2E,4E)-5-arylpenta-2,4-dienoic acid hydroxyamides.
REF 37J Med Chem. 2006 Jan 26;49(2):800-5.Aromatic sulfide inhibitors of histone deacetylase based on arylsulfinyl-2,4-hexadienoic acid hydroxyamides.
REF 38J Med Chem. 2003 Nov 20;46(24):5097-116.Histone deacetylase inhibitors.
REF 39Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells. Cancer Lett. 2003 Jan 28;189(2):197-206.
REF 40Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006 Sep;5(9):769-84.
REF 41Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.
REF 42Epigenetic modulation with HDAC inhibitor CG200745 induces anti-proliferation in non-small cell lung cancer cells. PLoS One. 2015 Mar 17;10(3):e0119379.
REF 43Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S20-6.
REF 44Clinical pipeline report, company report or official report of Celleron.
REF 45Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect. 2010 Sep;16(9):1482-7.
REF 46Bioorg Med Chem Lett. 2004 May 17;14(10):2617-20.Three new cyclostellettamines, which inhibit histone deacetylase, from a marine sponge of the genus Xestospongia.
REF 47Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Correction in: volume 4 on page 1369.
REF 48Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
REF 49ENTREMED TO ACQUIRE MIIKANA THERAPEUTICS. U.S. Securities and Exchange Commission. December 22, 2005.
REF 50J Med Chem. 2010 Mar 11;53(5):1937-50.Biological and biophysical properties of the histone deacetylase inhibitor suberoylanilide hydroxamic acid are affected by the presence of short alkyl groups on the phenyl ring.
REF 51Bioorg Med Chem Lett. 2008 Dec 1;18(23):6104-9. Epub 2008 Oct 14.SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
REF 52J Med Chem. 2007 Nov 15;50(23):5543-6. Epub 2007 Oct 17.Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
REF 53Bioorg Med Chem Lett. 2005 Apr 15;15(8):1969-72.Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors.
REF 54J Med Chem. 1999 Nov 4;42(22):4669-79.Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation.
REF 55Bioorg Med Chem Lett. 2009 Jun 1;19(11):3023-6. Epub 2009 Apr 20.Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity.
REF 56National Cancer Institute Drug Dictionary (drug id 698408).
REF 57Clinical pipeline report, company report or official report of Tetralogic pharmaceuticals.
REF 58Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
REF 59Bioorg Med Chem Lett. 2009 Apr 15;19(8):2346-9. Epub 2009 Feb 12.N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC)inhibitors.
REF 60Bioorg Med Chem Lett. 2009 May 15;19(10):2840-3. Epub 2009 Mar 26.Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
REF 61Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages. Blood. 2003 May 1;101(9):3451-9. Epub 2003 Jan 2.
REF 62Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009 Jun 16.
REF 63The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs. 2001;15(5):339-50.
REF 64Histone Deacetylase 2 is a Key Regulator of Diabetes and Transforming Growth Factor-{beta}1-Induced Renal Injury. Am J Physiol Renal Physiol. 2009 Jun 24.
REF 65Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
REF 66Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
REF 67Promising therapies in multiple myeloma. Blood. 2015 July 16; 126(3): 300-310.
REF 68US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
REF 69Clinical pipeline report, company report or official report of Phrma.org Leading Chronic Diseases Affecting Seniors 2014.
REF 70The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009 January; 10(1): 32-42.
REF 71Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
REF 72National Cancer Institute Drug Dictionary (drug id 703816).
REF 73US patent application no. 2009,0162,329, Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.